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Abstract: Background: Saliva tests that detect antibodies are used to diagnose HIV infection. The goal of this study was 
to determine whether saliva could be used for nucleic acid-based tests to measure HIV-1 virus load (VL) and detect drug 
resistance. 
Methods: 69 HIV infected individuals provided 5-10 ml of saliva and blood samples. Viral RNA was isolated from saliva 
and dried blood spots using the Nuclisens extraction. Saliva VL was measured using a modified Amplicor assay, and 
genotyping was performed using an in-house RT-PCR/sequencing protocol. Plasma VLs were obtained from concurrently 
drawn clinical tests. 
Results: Thirty-six of 47 (77%) plasma viremic patients had measurable saliva HIV-1 RNA. Paired plasma and saliva HIV 
RNA levels were significantly correlated (Spearman’s correlation = .6532, p<.0001), but saliva VL was typically lower. 
Three of 22 patients with undetectable plasma VL (<50 copies/ml) had detectable saliva HIV RNA. Eleven of 30 patients 
with undetectable saliva RNA had detectable plasma HIV-1 RNA. Comparison of the protease and reverse transcriptase 
gene sequences from paired saliva and plasma of 20 patients showed less than 1% difference overall, and few resistance-
related amino acid differences 
Conclusions: Most patients with plasma virus >50 copies/mL had detectable saliva HIV RNA, and the genotypic data was 
highly concordant between saliva and plasma. In patients with high levels of plasma HIV RNA, saliva might be useful in 
identifying viremia and evaluating drug resistance. 
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INTRODUCTION 
  The current standard of care for HIV-infected individuals 
includes routine monitoring of plasma virus load (VL) and 
genotypic testing for antiretroviral (ARV) drug resistance. In 
resource-rich as well as resource-limited public health 
settings, there is increasing demand for lower-cost and more 
feasible community-level virologic testing strategies for 
clinical monitoring and management of combination ARV 
therapy. The use of analyte alternatives to blood, particularly 
those that are easier to collect, have the potential to meet 
these demands. 
  Both HIV and anti-HIV antibodies can be detected in 
saliva  [1], providing an alternative to blood to detect HIV 
antibodies to diagnose HIV infection  [2]. Saliva HIV   
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antibody tests with specialized devices for proper saliva 
specimen collection are currently licensed by the U.S. Food 
and Drug Administration (FDA)  [3]. These tests are used in 
resource-limited settings as well as domestic public health 
clinics where rapid testing and ease of use are preferred [4]. 
The Centers for Disease Control (CDC) has included rapid 
HIV testing as part of its policy recommendations for HIV 
prevention programs [5]. The CDC has also recently 
promoted provider-initiated testing with reduced consent and 
counseling barriers, in order to increase accessibility to HIV 
testing and decrease the continued transmission of HIV [5, 
6]. 
  In voluntary counseling and testing centers, there is a 
growing interest in detecting acute infection among high-risk 
individuals. During acute infection, there is a brief period 
where high levels of HIV replication occur before the 
development of anti-HIV antibodies. Because VL levels are 
often greater than 100,000 copies/ml, methods to identify 
acutely-infected individuals include pooled screening of 
antibody negative plasma samples, which has substantially 
mitigated testing costs [7]. However, minimally invasive and 
lower cost sample collection methods have additional 
potential for increasing community-level identification of 
acute infection. Detection of HIV-1 in Saliva  The Open Virology Journal, 2010, Volume 4    89 
  VL and drug resistance testing using saliva can help meet 
the increasing demands to identify acute seroconverters, 
identify transmitted drug resistance in public health 
screening for acute infection, and scale up community-based 
treatment monitoring. Although saliva has been successfully 
used for antibody testing and for field diagnosis of HIV 
infection, the feasibility of nucleic acid testing to both detect 
acute infection and to monitor individuals receiving ARV 
treatment has not been thoroughly examined. We 
investigated the feasibility of using saliva to detect and 
quantify HIV-1 RNA and to genotype HIV-1. 
METHODS AND MATERIALS 
Study Population 
  Sixty-nine HIV infected individuals were enrolled in this 
study under informed consent: 40 recruited from the San 
Francisco City Clinic (approved by the UCSF Committee for 
Human Research) and 29 from the Peninsula AIDS Research 
Consortium clinic at the San Mateo County AIDS Program 
(approved by the Mills-Peninsula/San Mateo Clinical 
Research Committee IRB). These were patients attending 
clinic for HIV care or sexually transmitted disease services. 
Among 40 patients at the San Francisco City Clinic, a 
questionnaire was administered for inclusion and exclusion 
purposes. Questions included presence of oral ulcers or 
sores, current bleeding in mouth, and whether there was 
eating, drinking, brushing teeth, flossing or smoking in the 
past hour prior to saliva collections. A yes answer to any of 
the questions excluded the individual from participating in 
the study. 
Sample Collection 
  Patients provided 5-10 ml of saliva by spitting into a 
sterile cup. Dried blood spots (DBS) were prepared from 
finger sticks onto Whatman 903 filter paper (approximately 
50ul per DBS) and dried for several hours at room 
temperature prior to packaging and transporting to the 
processing lab. Saliva was frozen in the clinic and 
transported to the testing lab on dry ice. Both DBS and saliva 
were stored at -70c for up to two weeks prior to testing. 
Sample Processing 
RNA Extraction from Saliva and DBS 
  HIV-1 RNA plasma VLs were obtained from 
concurrently drawn clinical tests (Roche AMPLICOR HIV-1 
Monitor assay, version 1.5), when available, or performed in 
house from DBS. Sixty-four virus loads were obtained from 
plasma while 5 were obtained from DBS. Saliva was 
homogenized (500uL) and centrifuged at 800g for 10 min to 
pellet debris, and the resulting supernatant was ultra 
centrifuged at 23,885 x g for 30 min to pellet virus to match 
the identical ultracentrifugation performed to pellet virus in 
corresponding patient plasma samples. The pellet was re-
suspended in 9mL of Nuclisens lysis buffer. For DBS, spots 
were placed directly into 9mL of Nuclisens lysis buffer and 
agitated for 2 hours at room temperature. The Roche 
Amplicor internal quantification standard (QS) was added to 
each saliva or DBS sample dissolved in lysis buffer, and 
RNA extraction completed according to the Nuclisens 
protocol (Biomerieux, Durham NC, USA). From this point, 
HIV VL was quantified using the ultrasensitive Roche 
AMPLICOR HIV-1 Monitor assay, version 1.5 (Roche 
Molecular Diagnostics, Branchberg NJ, USA), according to 
the manufacturer’s instructions. DBS VL values were 
adjusted to account for sample volume input (50ul DBS). All 
VL values were normalized to 1 ml of fluid and expressed as 
RNA copies per ml. The lower limit of quantification was 
defined as 50 RNA copies/ml. 
Genotyping and Sequence Analysis 
  Genotyping was performed on samples with a VL greater 
than 200 copies/ml as previously described [8] when 
sufficient sample was available. Drug resistance mutations 
were identified using the Stanford HIV Drug Resistance 
Database (http://HIVDB.stanford.edu). Sequences were 
aligned with ClustalW [9] and a best-fit nucleotide 
substitution model was estimated using the program 
Modeltest [10] and manual examination in PAUP [11]. A 
maximum likelihood (ML) phylogenetic tree (Fig. 1) was 
constructed under this model with the program PhyML. 
Genetic distances between paired saliva and plasma 
sequences were estimated from this tree. 
RESULTS 
Validation of VL Determination from DBS and Saliva 
  Virus spiking experiments were performed to determine 
the best method for isolating RNA from saliva. High VL 
HIV-1 plasma of known copy was diluted to 50,000 
copies/mL, 10,000 copies/mL and 2,000 copies/mL in 
normal human plasma and saliva. HIV-1 RNA was 
successfully recovered from saliva and plasma using 
Ultrasensitive Roche AMPLICOR HIV-1 Monitor assay 
Extraction or the Ultrasensitive Nuclisens Extraction Kit. 
However, the Roche QS was not efficiently recovered from 
saliva using the Amplicor extraction method [12] (data not 
shown), resulting in inaccurate VL measurements. The 
Ultrasensitive Nuclisens Kit was able to recover both HIV-1 
and QS from spiked plasma and saliva as well as negative 
control samples with equal efficiency, and this method was 
used to extract RNA for both VL and genotype 
determinations. 
  In five cases, the timing and location of specimen 
acquisition did not include an appropriate plasma sample for 
VL determination. In these cases, DBS were assayed to 
determine plasma VL. To validate the use of DBS to 
measure VL, matched pairs of plasma and DBS were 
collected from 32 subjects, and VL (median DBS VL=5419, 
range=49-3,301,925copies/mL) determined on each 
specimen as described in Materials and Methods. Results 
(Fig. 2a) indicate a significant correlation between plasma-
derived and DBS derived VL values (p<0.0001). There was 
a median 0.18 log10  RNA copies/ml difference between 
plasma and DBS VL values. Based on the strong correlation 
and small differences between plasma and DBS VL, the five 
subjects with DBS-derived VL measurements were included 
in the study. 
Saliva Virus Load 
  Overall, HIV-1 RNA was detected in 47 of 69 (68%) 
plasma and 39 of 69 (56%) saliva specimens. Of the 47 
subjects with plasma viremia (median 22,514 copies/ml, 
range 68 to 1,244,229 copies/ml); 36 patients (77%) had 90    The Open Virology Journal, 2010, Volume 4  Balamane et al. 
measurable HIV RNA in saliva (median 75 copies/ml, range 
52 to 141,621 copies/ml). There was a significant correlation 
between plasma and saliva VL in these subjects (Fig. 2b, 
p<.0001). Patients with detectable saliva VL had a median 
plasma VL of 33,530 copies/ml, range 0 to 1,244,229 
copies/ml. Patients without detectable saliva had a median 
plasma VL of 0 copies/ml, and range 0 to 109,000 copies/ml 
Plasma VLs were higher than saliva VL levels by an average 
0.9 log10 RNA copies/ml. Two subjects exhibited a higher 
VL in saliva than in plasma, while three subjects had 
detectable HIV-1 RNA in saliva but had undetectable plasma 
VL. 
 
Fig. (1). Maximum likelihood phylogenetic tree of HIV-1 protease 
and reverse transcriptase genes comparing blood and saliva 
samples. (942 nucleotides total; PR codons 22-99 and RT codons 1-
238). 
 
Fig. (2a). Correlation of plasma HIV-1 RNA with DBS HIV-1 
RNA. 
 
Fig. (2b). Correlation of plasma HIV-1 RNA with saliva HIV-1 
RNA. 
Sequence Conservation and Drug Resistance Between 
Plasma and Saliva 
  To our knowledge, there is no previous literature reporting 
the sequencing of the gag-pol gene of HIV-1 from saliva 
specimens. A gag-pol fragment of nearly 1,000 base-pairs was 
sequenced from both plasma and saliva in 20 subjects. A 
phylogenetic tree showed that saliva and plasma sequences 
within individuals were 1) closely related (average genetic 
distance 0.0043 nucleotide substitutions/site; range 0.0011-
0.0196); 2) highly concordant (average genotypic concordance 
>99% at both the nucleotide and AA level); and 3) segregated 
)
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by subject. Thirteen subjects had genotypic resistance mutations 
in either plasma, saliva, or both (Table 1). In the protease (PR) 
gene, nine patients had minor resistance mutations (L10I, 
A71AV and A71V) with no major resistance mutations. 
Discordance in the presence of PR mutations between plasma 
and saliva was found in five subjects; in each case a minor PR 
mutation was found in the plasma that was not present in saliva. 
In the reverse transcriptase (RT) region, six patients were found 
to harbor resistance mutations (D67N, K103N, V108I, V118I, 
E138A, G190A and the revertant mutation T215S). Differences 
in RT resistance mutations were seen between plasma and 
saliva genotypes in four of six subjects; in two subjects 
mutations were identified in saliva but not plasma, and in two 
subjects mutations were found in plasma but not in saliva. In the 
PR gene 7/19 sequences demonstrated at least one difference 
between saliva and plasma in polymorphic residues associated 
with protease inhibitor resistance (secondary or minor 
mutations), while 4/19 RT sequences differed at major drug 
resistance codons. 
DISCUSSION 
  Previous studies have shown that non-plasma samples, 
including oral transudate, urine, and DBS, are appropriate 
analytes for the detection of antibodies to HIV to diagnose 
HIV infection  [2]. As a candidate diagnostic analyte, saliva 
can be easily obtained at lower cost and without the 
discomfort, invasiveness, and subsequent risks associated 
with needle use and disposal in conventional phlebotomy. 
Similarly, DBS provide an alternative means of blood 
collection for VL testing  [13]. We have found that among 
public health clinic patients, HIV-1 RNA could be 
successfully isolated, extracted, reverse transcribed and 
amplified from a relatively small volume of saliva (500ul). 
Comparison of viral RNA detection and quantification from 
saliva and plasma demonstrated that most subjects (83%) 
with more than 1,000 RNA copies/ml in plasma had 
detectable viral RNA in their oral secretions (Table 2a). 
Table  2a. Presence of HIV-1 RNA in Saliva at Different 
Plasma RNA levels (n=81) 
 
Plasma  
Virus Load  # Subjects  No. Subjects with  
Detectable Saliva RNA 
100,000-1,200,000 11  10  (91%) 
10,000-99,999 20  17  (85%) 
1,000-9,999 10  7  (70%) 
50-999 6  2  (33%) 
<50 22  3  (14%) 
HIV Negative Control  12  0 (0%) 
 
  Comparison of DBS and plasma for the detection and 
quantification of HIV-1 RNA showed good correlation (Fig. 
Table 1.  Protease and Reverse Transcriptase Mutations 
 
     Protease Reverse  Transcriptase 
Patient  Current ARV  Past ARV  Saliva  Blood  Saliva  Blood 
101  no  no  none none none none 
103 no  no  none  L10I D67N none 
104 no  no  A71AV A71AV,  L10I  none none 
105  no  no  none none none none 
108 no  no  none  L10I  none none 
110 no  yes  none  L10I  none none 
114 no  no  none  L10I  none none 
128  no  no  none none none none 
129 no  no  none  none  K103N K103N 
130 no  yes  none  none  none  K103N 
131  no  no  none none none none 
132 no  no  L10I L10I none none 
137 no  no  L10I L10I none none 
138 no  no  none  L10I  none none 
141  no  no  none none none none 
10047 unavailable  unavailable  none none none none 
30007 unavailable  n/a  none  A71V V118I  none 
123 yes  yes  none  none none none 
126 yes  yes  none  none  T215S, G190A  T215S, G190A, E138A 
10028 yes  n/a  none  none  V108I V108I 92    The Open Virology Journal, 2010, Volume 4  Balamane et al. 
2a). This is consistent with a growing literature in which 
dried blood spots have been evaluated in comparison to 
plasma  [14]. As expected from previous studies  [15, 16], 
VL in saliva contained less HIV-1 RNA compared to 
plasma, however most viremic patients in our study had 
detectable saliva RNA. Overall, the sensitivity of saliva VL 
was found to be 77% compared to plasma (Table 2b). 
Sensitivity could be low for technical or biological reasons. 
There might not be any HIV present in the saliva 
compartment for some patients due to no localized 
replication. While this sensitivity may be insufficient to 
monitor patients on suppressive ARV, the high proportion of 
saliva RNA-positivity when plasma VL is higher (95% at 
plasma VL > 33,500 copies/ml) may make saliva a suitable 
analyte for evaluating untreated or acutely-infected 
individuals. 
Table  2b. Sensitivity of Saliva HIV-1 Virus Load Detection 
(n=69) 
 
 Saliva  (95%CI) 
Sensitivity  .77(.62-.87) 
 
  Although HIV-1 is transmitted through blood, semen, 
breast milk, and cervical secretions, the evidence for 
transmissible virus in saliva is less convincing [17]. In the 
past, researchers have found that VL from non blood sources 
can be 1 to 2 log values lower than VL from corresponding 
plasma samples. The relatively low level of virus in saliva 
(median saliva VL= 75copies/mL) may be one explanation 
for the apparent infrequency of transmission of virus from 
saliva  [18, 19]. However, transmission rates are higher in 
other non blood analytes than in saliva regardless of lower 
VLs in those compartments. There is proposed evidence to 
suggest existence of anti viral activity in the oral 
environment preventing HIV-1 transmission  [19]. We were 
surprised to identify three individuals who had detectable 
saliva VL while having a plasma VL of < 50 copies/ml. In 
addition we found two individuals with saliva HIV-1 RNA 
levels (> 20,000 copies/ml) that were 2 to 5-fold greater than 
their respective plasma levels. It is possible that undetected 
inflammatory responses in the oral cavity may have 
increased the VL in the patients’ respective saliva. Although 
multiple studies of HIV-1 RNA in virus particles from non-
blood fluids have shown evidence for compartmentalized 
viral replication [12], in our study, it is unclear if 
independent replication is occurring in different biological 
compartments. In the present analysis, differences in the 
detection and quantification of viral RNA in a small number 
of subjects suggest that the oral cavity may support 
compartmental replication and shedding in HIV-infected 
individuals and these rates of replication may be different for 
different patients. However, further studies need to be 
performed to further evaluate this as inflammatory 
conditions of the mouth were not closely examined. 
  Several viral characteristics may be inferred from 
sequence analysis of HIV RNA including subtype, diversity  
[20], drug resistance  [21] and envelope tropism  [22]. Our 
phylogenetic comparisons of gag-pol gene sequences 
obtained from DBS, plasma and saliva showed considerable 
sequence homology and provided assurance that sample-
mix-up or contamination did not occur. These findings are in 
agreement with previous studies where sequencing of the 
envelope gene in saliva and plasma was concordant  [22]. 
However, while comparison of plasma and saliva HIV-1 pol-
genes demonstrated only modest overall differences (<1%) 
in nucleic and amino acid sequences from each 
compartment, examination of specific codons suggest 
potentially important differences between saliva and plasma 
virus. In 8/20 patients, drug-associated resistance mutations 
in the PR and/or RT gene were found in only one 
compartment. These differences were primarily found at 
minor mutation sites in our population of primarily untreated 
patients, except for one treated patient where a K103N 
mutation was found in plasma-associated virus but not in 
saliva. While it is possible that sampling bias may have 
affected our ability to detect mutations in different 
compartments, all of the samples genotyped met similar viral 
load criteria (>200 copies/ml) to be included in the analysis. 
Our findings of different genotype profiles in plasma vs 
saliva suggest variations in selective pressure between these 
two compartments. Further analysis of resistance mutations 
between saliva and plasma in highly ARV experienced 
patients is needed to further evaluate this hypothesis. 
  In summary, saliva may be a useful analyte for detection 
of HIV-1 when HIV-1 RNA levels are high, such as in acute 
HIV infection. In monitoring responses to ARV therapy, 
saliva VL measures have reduced sensitivity and may not 
accurately reflect VL in plasma, but nevertheless could 
identify high-level viremia during treatment failure. The use 
of HIV-1 sequences to monitor drug resistance may be 
possible, although additional analysis of compartmental 
differences is needed. Further studies on compartmental 
differences in HIV viremia and drug resistance can help 
optimize saliva testing as an alternative analyte for 
monitoring patients in clinical settings. 
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